Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum S100B can be used as a biomarker of depression.
|
30745657 |
2020 |
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ANCOVA analysis followed by heteroscedasticity-consistent covariance matrix was performed to evaluate BDNF and S100B levels, adjusted for depression severity, pain levels and use of analgesics according different pathologies.
|
31100426 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Using a cohort of 86 pregnant women, we found that SSRIs significantly increase BDNF levels in late pregnancy and that S100B, but not BDNF, is associated with maternal depression in SSRI-treated women only.
|
30506371 |
2019 |
Depressive disorder
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with S100B levels in the intermediate tertile, that is, between 33 ng/L and 53 ng/L, had higher odds on remission, odds ratio: 5.5 (95%Confidence Interval (CI): 1.55-19.20, p = <0.01), and were more likely to remit from depression over time, hazard ratio: 1.96 (95%CI: 1.04-3.72, p = 0.04), compared with patients in the lowest tertile.
|
31493698 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Notably, ketamine increased the proliferation of NPCs independent of the NMDA receptor, while transcriptome analysis revealed significant upregulation of insulin-like growth factor 2 (IGF2) and p11, a member of the S100 EF-hand protein family, which are both implicated in the pathophysiology of depression, 24 h after ketamine treatment.
|
31554266 |
2019 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
EGb, as an adjunctive treatment, can effectively improve depressive symptoms and reduce expression of serum S100B, which is a marker of brain injury, suggesting that EGb restores neurologic function during the treatment of depression in elderly patients and S100B participates in the therapeutic mechanism.
|
30278520 |
2018 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alpha1-antitrypsin (A1AT), FAS, Heparin-binding EGF-like Growth Factor (HB-EGF), Insulin-like Growth Factor-1 (IGF-1), Luteinizing Hormone (LH), Macrophage Inflammatory Protein type 1 alpha (MIP-1α), Resitin, S100b, Tissue Inhibitor of Metalloproteinase type 1 (TIMP-1), and Vascular Cell Adhesion Molecule type 1 (VCAM-1) each were partial mediators of depression's association with δ.
|
28594820 |
2017 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens.
|
20962330 |
2010 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Significant differences in the subgroup depression (first-episode and recurrent depression) were also shown in 3 genotypes of S100B rs9722 and rs11911834 in patients and control subjects (P < 0.05).
|
19497163 |
2009 |
Depressive disorder
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Significant differences in the subgroup depression (first-episode and recurrent depression) were also shown in 3 genotypes of S100B rs9722 and rs11911834 in patients and control subjects (P < 0.05).
|
19497163 |
2009 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although it may be open for discussion whether the neuroprotective effects of ONO-2506 are exclusively due to its inhibition of S100B synthesis, the latter action of ONO-2506 warrants studies of the effects of this drug in the pathobiology of depression.
|
16797859 |
2006 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
Although it may be open for discussion whether the neuroprotective effects of ONO-2506 are exclusively due to its inhibition of S100B synthesis, the latter action of ONO-2506 warrants studies of the effects of this drug in the pathobiology of depression.
|
16797859 |
2006 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
S100 beta, a calcium binding brain protein expressed by astrocytes, has been shown to be involved in higher neural processes, including hippocampal-dependent behavioral traits and hippocampal neuronal long-term potentiation (LTP) and depression (LTD), neurophysiological phenomena that may be involved in exploring, learning and remembering novel stimuli.
|
8804639 |
1996 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
PSYGENET |
S100 beta, a calcium binding astrocytic brain protein, influences hippocampal long-term potentiation (LTP) and depression (LTD), synaptic processes suggested to play role in spatial (contextual) learning and memory.
|
8840925 |
1996 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
S100 beta, a calcium binding brain protein expressed by astrocytes, has been shown to be involved in higher neural processes, including hippocampal-dependent behavioral traits and hippocampal neuronal long-term potentiation (LTP) and depression (LTD), neurophysiological phenomena that may be involved in exploring, learning and remembering novel stimuli.
|
8804639 |
1996 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
S100 beta, a calcium binding astrocytic brain protein, influences hippocampal long-term potentiation (LTP) and depression (LTD), synaptic processes suggested to play role in spatial (contextual) learning and memory.
|
8840925 |
1996 |